Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Actoxumab, an antibody targeting Clostridium difficile Toxin A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bococizumab, an antibody targeting PCSK9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vadastuximab, an antibody targeting SIGLEC3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rovalpituzumab, an antibody targeting DLL3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Glembatumumab, an antibody targeting GPNMB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Suvratoxumab, an antibody targeting Staphylococcus aureus Toxin A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Depatuxizumab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Andecaliximab, an antibody targeting MMP9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Otilimab, an antibody targeting CSF2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ontamalimab, an antibody targeting MADCAM1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Birtamimab, an antibody targeting SAA1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Upinitatug, an antibody targeting SLC34A2.